Upadacitinib versus placebo or adalimumab with background methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate: a subgroup analysis of a phase III randomized controlled trial in Central and Eastern European patients

類似資料

• Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
  著者:: Fleischmann, Roy M, 等
  出版事項: (2019)
• Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries
  著者:: Codreanu, Catalin, 等
  出版事項: (2015)
• Musculoskeletal ultrasonography in routine rheumatology practice: data from Central and Eastern European countries
  著者:: Mandl, Peter, 等
  出版事項: (2016)
• Biologics, cardiovascular effects and cancer
  著者:: Damjanov, Nemanja, 等
  出版事項: (2014)
• Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries
  著者:: Orlewska, Ewa, 等
  出版事項: (2011)